H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on BridgeBio (BBIO) to $70 from $56 and keeps a Buy rating on the shares following the Q2 report. The firm says Acoramidis uptake remains ahead of its projections while BridgeBio has multiple pipeline catalysts.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO: